A community study of high density lipoproteins in adult noninsulin-dependent diabetics.
A community study of high density lipoproteins in adult noninsulin-dependent diabetics.
复制标题
成人非胰岛素依赖型糖尿病患者高密度脂蛋白的社区研究。
DOI：
10.1093/oxfordjournals.aje.a113529
复制
发表时间：
1983
影响因子：
5
通讯作者：
Holdbrook,M
中科院分区：
文献类型：
--
作者：
Barrett-Connor,E;Witztum,JL;Holdbrook,M
Barrett-Connor，E.社区和家庭医学，加州大学圣地亚哥分校，拉霍亚，加利福尼亚州92093)，J.L.维茨图姆和M.霍德布鲁克。一项关于成人非胰岛素依赖型糖尿病患者高密度脂蛋白的社区研究.流行病学杂志1983；117：186-92.人们普遍认为高密度脂蛋白胆固醇(HDLC)对心血管疾病有保护作用，糖尿病患者患心血管疾病的风险较高.以前对非胰岛素依赖型糖尿病患者的高密度脂蛋白-C水平的研究报道了不同的结果，可能是由于病例选择或未能调整已知的影响高密度脂蛋白-C的协变量，如肥胖、吸烟、饮酒、运动或外源性雌激素使用。作者将南加州一项人口调查中发现的97名有病史或空腹高血糖的成年非胰岛素依赖型糖尿病患者与来自同一社区的194名年龄和性别匹配的正常血糖对照组进行了比较。男女非胰岛素依赖型糖尿病患者的高密度脂蛋白胆固醇水平均显著降低，在对女性的肥胖、吸烟、饮酒、运动和雌激素使用进行调整后，这些差异仍然存在。这些数据支持这样一个概念，即降低高密度脂蛋白胆固醇水平可能是糖尿病患者心血管疾病风险过高的一个机制。与已发表的文献相反，接受甲苯磺丁胺治疗的糖尿病患者的高密度脂蛋白胆固醇水平与节食治疗相比没有显著差异。这一发现并不支持这样一种说法，即大学组糖尿病项目报告的服用甲苯丁胺的糖尿病患者心血管疾病死亡的额外风险是由于甲苯丁胺诱导的高密度脂蛋白-C降低的结果。
Barrett-Connor, E. (Dept. of Community and Family Medicine, U. of California, San Diego, La Jolla, CA 92093), J. L. Witztum and M. Holdbrook. A community study of high density lipoproteins in adult noninsulin-dependent diabetics.Am J Epidemiol1983; 117: 186–92.It is generally accepted that high density lipoprotein cholesterol (HDL-C) is protective against cardiovascular disease, and that diabetics are at a significant excess risk of cardiovascular disease. Previous studies of HDL-C levels in noninsulin-dependent diabetics have reported divergent results, possibly due to case selection or failure to adjust for covariables known to effect HDL-C, such as obesity, cigarette smoking, alcohol intake, exercise, or exogenous estrogen use. The authors compared 97 adult noninsulin-dependent diabetics identified by history or fasting hyperglycemia from a population survey in southern California with 194 age- and sex-matched euglycemic controls from the same community. HDL-C levels were significantly lower in noninsulin-dependent diabetics of both sexes, and these differences persisted after adjustment for obesity, cigarette smoking, alcohol, exercise, and estrogen use in women. These data support the concept that reduced levels of HDL-C may be one mechanism whereby diabetics experience an excess risk of cardiovascular disease. In contrast to the published literature, HDL-C levels were not significantly different in diabetics treated with tolbutamide vs. diet therapy. This finding does not support the suggestion that the excess risk of cardiovascular disease mortality in diabetics assigned to tolbutamide reported from the University Group Diabetes Program was a consequence of tolbutamide-induced reductions in HDL-C.